BackEucrates Biomedical Acquisition Overview

Eucrates Biomedical Acquisition Receivables

Eucrates Biomedical Acquisition's receivables is $0.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer average

Loading

Eucrates Biomedical Acquisition Receivables History

Loading

Eucrates Biomedical Acquisition vs. peers: Receivables Comparison

Loading

Eucrates Biomedical Acquisition Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Eucrates Biomedical Acquisition (EUCR) FAQ

Eucrates Biomedical Acquisition posts a receivables of $0 as of December 2022. In the prior-year period, the figure was $0. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Eucrates Biomedical Acquisition's receivables was $0. The latest reading is $0 (period ending December 2022). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of Eucrates Biomedical Acquisition's financial statement story. At $0, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for EUCR's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Eucrates Biomedical Acquisition's other metric pages and overview cover the third.